RedHill Biopharma boosts ADS ATM capacity with new 6-K filing

Rhea-AI Filing Summary

RedHill Biopharma Ltd. (RDHL) reports that on November 26, 2025 it filed a prospectus supplement to increase the maximum aggregate offering amount of American Depositary Shares (ADSs) that may be issued and sold under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally entered into on February 3, 2025. Each ADS represents 10,000 ordinary shares of RedHill, with a par value of NIS 0.01 per share.

The report also notes that legal opinions and related consents from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP are filed as exhibits, and that this Form 6-K is incorporated by reference into multiple existing RedHill registration statements on Forms S-8 and F-3.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RedHill Biopharma (RDHL) announce in this November 2025 Form 6-K?

RedHill Biopharma announced that it filed a prospectus supplement to increase the maximum aggregate offering amount of its American Depositary Shares that may be issued and sold from time to time under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC.

What is the structure of RedHill Biopharma’s ADSs mentioned in the Form 6-K?

Each American Depositary Share of RedHill Biopharma represents 10,000 ordinary shares of the company, each with a par value of NIS 0.01 per share.

Which agreement governs RedHill Biopharma’s at-the-market offering program?

The at-the-market offering program is governed by an At The Market Offering Agreement that RedHill Biopharma entered into with H.C. Wainwright & Co., LLC on February 3, 2025.

Which legal opinions are included as exhibits in this RedHill Biopharma Form 6-K?

The exhibits include an opinion of Goldfarb Gross Seligman & Co. (Exhibit 5.1), an opinion of Haynes and Boone, LLP (Exhibit 5.2), and related consents in Exhibits 23.1 and 23.2.

How is this RedHill Biopharma Form 6-K used with existing registration statements?

The Form 6-K is incorporated by reference into RedHill’s previously filed Form S-8 and Form F-3 registration statements, allowing the new information to be part of those effective offerings.

Does this Form 6-K indicate who signed the report for RedHill Biopharma?

Yes. The report is signed on behalf of RedHill Biopharma by Dror Ben-Asher, who is identified as the company’s Chief Executive Officer, dated November 26, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 04:02 PM Learn about SEC filing dates

 UNITED STATES   

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of November 2025
Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha’arba’a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐

 
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 
On November 26, 2025, RedHill Biopharma Ltd. (the “Company”) filed a prospectus supplement to increase the maximum aggregate offering amount of the American Depositary Shares, each representing ten thousand (10,000) of its ordinary shares, par value NIS 0.01 per share, that may be issued and sold from time to time under the At The Market Offering Agreement that the Company entered into with H.C. Wainwright & Co., LLC on February 3, 2025.

Attached hereto and incorporated by reference in this Report on Form 6-K are the following exhibits:

Exhibit 5.1: Opinion of Goldfarb Gross Seligman & Co.

Exhibit 5.2: Opinion of Haynes and Boone, LLP.

Exhibit 23.1: Consent of Goldfarb Gross Seligman & Co. (included in Exhibit 5.1).

Exhibit 23.2: Consent of Haynes and Boone, LLP (included in Exhibit 5.2).

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327) and on March 25, 2025 (File No. 333-286082), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the “Registrant”)
Date: November 26, 2025	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer